ArticleMolecules (Basel, Switzerland)2022
Biotransformation of Liquiritigenin into Characteristic Metabolites by the Gut Microbiota.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Pharmacological Effects of Wenjing Decoction in a Rat Model of Cold Coagulation and Blood Stasis Primary Dysmenorrhea: An Integrated Analysis of Serum Pharmacochemistry, Network Pharmacology and Metabolomics.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Zhenyuan Solid Drink Ameliorates Inflammation and Oxidative Stress in Isoproterenol-Induced Ischemic Myocardial Infarction via TLR4/NF-κB Pathway and PI3K/AKT1/NRF2 Pathway in Rats.Food science & nutrition · 2026Article
- Multi-omics profiling reveals microbial regulation of a key aromatic ester phenethyl acetate formation in fermented alfalfa and its impact on sheep feed preference.Food chemistry: X · 2025Article
- Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer.Cancers · 2025Review
- Bridging traditional Chinese medicine and Alzheimer's disease: the pivotal role of gut microbiota in multitarget therapeutic mechanisms.Frontiers in pharmacology · 2025Review
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome.mSystems · 2024Article
- Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications.Frontiers in pharmacology · 2024Review
- Neuro-Nutraceutical Polyphenols: How Far Are We?Antioxidants (Basel, Switzerland) · 2023Review
- Biosynthetic Gene Clusters from Swine Gut Microbiome.Microorganisms · 2023Article
- The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
The bioavailability of flavonoids is generally low after oral administration. The metabolic transformation of flavonoids by the gut microbiota may be one of the main reasons for this, although these metabolites have potential pharmacological activities. Liquiritigenin is an important dihydroflavonoid compound found in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.